Cargando…

Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays

The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein p...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposito, Dominic, Mehalko, Jennifer, Drew, Matthew, Snead, Kelly, Wall, Vanessa, Taylor, Troy, Frank, Peter, Denson, John-Paul, Hong, Min, Gulten, Gulcin, Sadtler, Kaitlyn, Messing, Simon, Gillette, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271859/
https://www.ncbi.nlm.nih.gov/pubmed/32504802
http://dx.doi.org/10.1016/j.pep.2020.105686
_version_ 1783542151552958464
author Esposito, Dominic
Mehalko, Jennifer
Drew, Matthew
Snead, Kelly
Wall, Vanessa
Taylor, Troy
Frank, Peter
Denson, John-Paul
Hong, Min
Gulten, Gulcin
Sadtler, Kaitlyn
Messing, Simon
Gillette, William
author_facet Esposito, Dominic
Mehalko, Jennifer
Drew, Matthew
Snead, Kelly
Wall, Vanessa
Taylor, Troy
Frank, Peter
Denson, John-Paul
Hong, Min
Gulten, Gulcin
Sadtler, Kaitlyn
Messing, Simon
Gillette, William
author_sort Esposito, Dominic
collection PubMed
description The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein produced from transient transfection of HEK293 cells will be a limiting factor for these assays. To improve the yield of spike protein and support the high demand for antigens in serology assays, we investigated several recombinant protein expression variables by altering the incubation temperature, harvest time, chromatography strategy, and final protein manipulation. Through this investigation, we developed a simplified and robust purification strategy that consistently yields 5 mg of protein per liter of expression culture for two commonly used forms of the SARS-CoV-2 spike protein. We show that these proteins form well-behaved stable trimers and are consistently functional in serology assays across multiple protein production lots.
format Online
Article
Text
id pubmed-7271859
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-72718592020-06-05 Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays Esposito, Dominic Mehalko, Jennifer Drew, Matthew Snead, Kelly Wall, Vanessa Taylor, Troy Frank, Peter Denson, John-Paul Hong, Min Gulten, Gulcin Sadtler, Kaitlyn Messing, Simon Gillette, William Protein Expr Purif Article The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein produced from transient transfection of HEK293 cells will be a limiting factor for these assays. To improve the yield of spike protein and support the high demand for antigens in serology assays, we investigated several recombinant protein expression variables by altering the incubation temperature, harvest time, chromatography strategy, and final protein manipulation. Through this investigation, we developed a simplified and robust purification strategy that consistently yields 5 mg of protein per liter of expression culture for two commonly used forms of the SARS-CoV-2 spike protein. We show that these proteins form well-behaved stable trimers and are consistently functional in serology assays across multiple protein production lots. Elsevier Inc. 2020-10 2020-06-04 /pmc/articles/PMC7271859/ /pubmed/32504802 http://dx.doi.org/10.1016/j.pep.2020.105686 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Esposito, Dominic
Mehalko, Jennifer
Drew, Matthew
Snead, Kelly
Wall, Vanessa
Taylor, Troy
Frank, Peter
Denson, John-Paul
Hong, Min
Gulten, Gulcin
Sadtler, Kaitlyn
Messing, Simon
Gillette, William
Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_full Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_fullStr Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_full_unstemmed Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_short Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_sort optimizing high-yield production of sars-cov-2 soluble spike trimers for serology assays
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271859/
https://www.ncbi.nlm.nih.gov/pubmed/32504802
http://dx.doi.org/10.1016/j.pep.2020.105686
work_keys_str_mv AT espositodominic optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT mehalkojennifer optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT drewmatthew optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT sneadkelly optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT wallvanessa optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT taylortroy optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT frankpeter optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT densonjohnpaul optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT hongmin optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT gultengulcin optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT sadtlerkaitlyn optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT messingsimon optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT gillettewilliam optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays